EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY-NC-ND 4.0

Lipoprotein(a) Particle Core Remodeling and Apolipoprotein C-III Inhibition

Dick C Chan, Gerald F Watts

JACC: Basic to Translational Science · 2026-10 · 11 (10) · 101697

DOI: 10.1016/j.jacbts.2026.101697 ↗

Kurz gefasst

Editorial in der Zeitschrift JACC: Basic to Translational Science, 2026-10. Verfasst von Dick C Chan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Western Australia, Perth, Australia. Electronic address: dick.chan@uwa.edu.au. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ipoprotein(a) (Lp(a)) is an established, geneti- cally determined risk factor for atherosclerotic cardiovascular disease (ASCVD), myocardial infarction, and calcific aortic valve stenosis.1 Its atherogenicity is multifaceted, primarily driven by elevated particle numbers and the structural properties of apolipoprotein(a) (apo(a)), including high content of proinflammatory oxidized phospholipids (OxPLs). 1 Although human Lp(a) metabolism remains incompletely understood, emerging evidence highlights complex metabolic and structural interactions of Lp(a) with triglyceride-rich lipoproteins (TRLs), including very-low-density lipoprotein (VLDL), chylomicrons, and their remnants.2 Understanding the metabolism of Lp(a) in hypertriglyceridemic states is important to advancing our understanding of its role in ASCVD.Standard lipid-lowering therapies for hypertriglyceridemia (HTG), including fibrates and omega-3 fatty acid supplementation, can reduce plasma triglyceride concentrations by up to 30%, whereas insulin sensitizers (eg, pioglitazone) and GLP-1 receptor agonists exert more modest effects (10%-20% reduction).3 Each of these agents lowers apolipoprotein C-III (apoC-III) to varying degrees via distinct mechanisms.Emerging therapies targeting APOC3 achieve far greater triglyceride reductions and

Schlagwörter

Stichwörter der Autor:innen

apoC-IIIcholesterollipoprotein(a)triglycerides

Autor:innen und Institutionen

  • Medical School, University of Western Australia, Perth, Australia. Electronic address: dick.chan@uwa.edu.au.
  • Medical School, University of Western Australia, Perth, Australia; Department of Cardiology and Internal Medicine, Cardiometabolic Clinic, Royal Perth Hospital, Perth, Australia.

Zitieren

APA

Chan, D. C., & Watts, G. F. (2026). Lipoprotein(a) Particle Core Remodeling and Apolipoprotein C-III Inhibition. JACC: Basic to Translational Science, 11(10), 101697. https://doi.org/10.1016/j.jacbts.2026.101697

Vancouver

Chan DC, Watts GF. Lipoprotein(a) Particle Core Remodeling and Apolipoprotein C-III Inhibition. JACC: Basic to Translational Science. 2026;11(10):101697. doi:10.1016/j.jacbts.2026.101697

BibTeX
@article{Chan2026,
  author = {Chan, Dick C and Watts, Gerald F},
  title = {Lipoprotein(a) Particle Core Remodeling and Apolipoprotein C-III Inhibition},
  journal = {JACC: Basic to Translational Science},
  year = {2026},
  volume = {11},
  number = {10},
  pages = {101697},
  doi = {10.1016/j.jacbts.2026.101697}
}
Kostenlos starten →